Company Valuation: HLS Therapeutics Inc.

Data adjusted to current consolidation scope
Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027 2028
Market Cap 1 384.6 235.2 95.92 86.84 109.9 91.27 - -
Change - -38.85% -59.22% -9.47% 26.6% -16.98% - -
Enterprise Value (EV) 384.6 235.2 95.92 86.84 109.9 91.27 91.27 91.27
Change - -38.85% -59.22% -9.47% 26.6% -16.98% 0% 0%
P/E -28.9x -9.95x -3.52x -4.41x -9.01x -14.6x -97.3x 41.7x
PBR - 1.88x - 1.22x - 1.59x 1.54x -
PEG - -0.1x -0.2x 0.2x 0.2x 0.3x 1.1x -0x
Capitalization / Revenue 6.41x 3.83x 1.52x 1.53x 1.98x 1.57x 1.42x 1.18x
EV / Revenue 0x 0x 0x 0x 0x 1.57x 1.42x 1.18x
EV / EBITDA 0x 0x 0x 0x 0x 4.72x 3.89x 2.8x
EV / EBIT -0x -0x -0x -0x -0x -21.7x 60.8x 13x
EV / FCF 0x 0x 0x 0x 0x 8.69x - -
FCF Yield 3.27% 7.18% 16.4% 9.2% 15.4% 11.5% - -
Dividend per Share 2 - - 0.7398 - - - - -
Rate of return - - 24.7% - - - - -
EPS 2 -0.41 -0.73 -0.85 -0.62 -0.39 -0.2 -0.03 0.07
Distribution rate - - -87% - - - - -
Net sales 1 60.01 61.47 63.07 56.62 55.5 58.03 64.31 77.2
EBITDA 1 26.33 23.83 21.05 16.65 19.62 19.34 23.45 32.65
EBIT 1 -6.284 -13.5 -10.35 -7.686 -4.106 -4.2 1.5 7
Net income 1 -13.12 -23.6 -27.53 -19.66 -12.43 -6.264 -1.05 2.6
Net Debt - - - - - - - -
Reference price 2 11.853 7.263 2.991 2.731 3.515 2.918 2.918 2.918
Nbr of stocks (in thousands) 32,451 32,384 32,071 31,793 31,274 31,275 - -
Announcement Date 3/17/22 3/16/23 3/14/24 3/13/25 3/12/26 - - -
1USD in Million2USD
Estimates

P/E, Detailed evolution

P/E (N) EV / Sales (N) EV / EBITDA (N) Dividend Yield (N) Capi.($)
19.5x0.24x13.5x0.4% 96.53B
29.05x0.23x14.6x0.91% 52.93B
44.98x3.18x29.49x1.38% 23.01B
11.61x0.2x4.88x2.61% 8.23B
13.65x1.05x8.41x2.49% 7.87B
5.96x0.1x2.66x4.97% 6.74B
9.3x1.74x5.56x3.53% 6.22B
25.41x1.2x15.13x2.91% 5.31B
10.83x0.12x4.49x4.13% 3.72B
Average 18.92x 0.89x 10.97x 2.59% 23.4B
Weighted average by Cap. 23.42x 0.65x 14.30x 1.17%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA

  1. Stock Market
  2. Stocks
  3. HLS Stock
  4. HLTRF Stock
  5. Valuation HLS Therapeutics Inc.